CannEpil exclusive global licensing for drug-resistant epilepsy marks a major turning point in seizure care. Under this deal, Splash Beverage Group secures rights to develop and commercialize CannEpil worldwide. As a result, patients and clinicians may soon access a regulated, pharmaceutical-grade cannabinoid option.
Because roughly thirty percent of people with epilepsy do not respond to current medicines, new therapies matter. This licensing signals faster regulatory pathways, expanded clinical research, and stronger commercial backing. Therefore, CannEpil could shift treatment paradigms for drug-resistant epilepsy and spur investment in next-generation cannabinoid therapeutics. Moreover, the agreement includes rights to reformulations and sublicensing for a twenty-year initial term with performance incentives.
Investors have already shown support through a $1 million strategic commitment to advance U.S. regulatory steps. Consequently, the program plans to expand clinical evidence and engage leading U.S. epilepsy investigators. For patients with refractory seizures, this could mean more treatment options and renewed hope.
What is CannEpil exclusive global licensing?
CannEpil exclusive global licensing for drug-resistant epilepsy gives Splash Beverage Group sole worldwide development rights. It allows worldwide commercialization, distribution, and sublicensing of the EU-GMP cannabinoid product for refractory seizure disorders. The deal includes reformulation rights and a twenty-year initial term, thereby accelerating global regulatory filings, trials, and patient access.
CannEpil exclusive global licensing for drug-resistant epilepsy details
Splash Beverage Group Inc. secured exclusive global rights to CannEpil from Argent BioPharma Limited. Under the agreement, Splash can develop, commercialize, market, distribute, sublicense, and sell CannEpil worldwide. The license covers treatment of drug-resistant epilepsy, refractory epilepsy, seizure disorders, and related neurological conditions.
Geographically, the deal spans all territories. CannEpil is already manufactured to EU-GMP standards and is available in Ireland, the United Kingdom, Germany and Australia. Moreover, the license grants rights to future reformulations and next generation product improvements.
The agreement includes a twenty-year initial term and sublicensing rights for strategic pharmaceutical partners. Argent BioPharma will receive a royalty equal to 15% of net revenue. Additionally, Argent received debt forgiveness of about $5 million, and Splash agreed to issue $5.5 million of preferred equity as part of the consideration.
Key deal points
- Exclusive worldwide development, commercialization, and distribution rights
- Initial twenty-year term with sublicense authority
- Fifteen percent royalty on net revenue to Argent BioPharma
- Rights to reformulations and next-generation product developments
- Approximately $5 million debt forgiveness and $5.5 million preferred equity issuance
- One million dollar strategic investment to support U.S. regulatory activities
Because roughly thirty percent of people with epilepsy do not respond to medicines, the focus on drug-resistant epilepsy matters. For context, the U.S. National Institute of Neurological Disorders and Stroke notes the estimate for medically intractable epilepsy here and the World Health Organization reports control and treatment statistics here. Consequently, the license aims to accelerate regulatory filings, expand clinical evidence, and improve patient access globally.
Benefits of CannEpil exclusive global licensing for drug-resistant epilepsy
The exclusive global licensing of CannEpil can expand treatment choices for patients with refractory seizures. Therefore, the agreement aims to speed regulatory filings, broaden clinical trials, and improve global access to a pharmaceutical-grade cannabinoid option.
Because roughly thirty percent of people with epilepsy do not respond to medicines, this focus matters for public health. The World Health Organization estimates about 70 percent of patients respond to treatment, which implies roughly 30 percent remain medication-resistant source.
The Epilepsy Foundation defines drug-resistant epilepsy as seizures that persist after two appropriate antiseizure medicines. Consequently, targeted therapies and clinical research become critical for these patients source.
Key patient benefits
- Improved availability because Splash secured worldwide commercialization and sublicensing rights
- Faster innovation due to reformulation and next generation product development rights
- Greater trial access as the program expands clinical and real-world evidence globally
- Better reimbursement prospects where national programs exist, enhancing affordability
- More consistent quality from EU-GMP manufacturing and regulated supply chains
- Increased investment in U.S. development and investigator engagement, which may speed approvals
In short, the license could translate into more treatment options and better outcomes for people with refractory epilepsy. Consequently, patients and clinicians may gain new tools to manage seizures more effectively.
CannEpil versus other epilepsy treatments
| Treatment Name | Method of Action | Effectiveness | Availability | Side Effects |
|---|---|---|---|---|
| CannEpil | Pharmaceutical-grade cannabinoid acting on the endocannabinoid system as an adjunctive investigational therapy | Early clinical and real-world evidence shows seizure reductions in some refractory patients; formal trials ongoing | Available in Ireland, UK, Germany and Australia; worldwide commercialization licensed to Splash and investigational in other markets | Generally mild to moderate; somnolence and gastrointestinal effects reported; safety profile under continued evaluation |
| Epidiolex (purified cannabidiol) | Modulates neuronal excitability through multiple pathways including endocannabinoid signaling | Proven to reduce seizures in Dravet syndrome and Lennox-Gastaut syndrome in randomized trials | FDA approved in the United States and prescribed internationally | Somnolence, decreased appetite, elevated liver enzymes, drug interactions |
| Levetiracetam | Binds synaptic vesicle protein 2A to reduce abnormal neuronal firing | Effective for many focal and generalized seizures but some patients remain medication-resistant | Widely available as a generic antiseizure medication | Behavioral changes, irritability, dizziness |
| Vagus Nerve Stimulation | Implanted device delivers intermittent electrical stimulation to the vagus nerve to modulate brain circuits | Offers moderate seizure reduction as adjunctive therapy for refractory epilepsy | Offered at specialized epilepsy centers; requires surgical implantation | Voice changes, cough, implant-site pain, infection risk |
| Resective Epilepsy Surgery | Surgical removal of the epileptogenic brain region to stop seizure generation | Can be curative for selected candidates with focal epilepsy when seizures are localized | Performed in specialized epilepsy surgery programs after multidisciplinary evaluation | Surgical risks, potential neurological deficits depending on resection site |
| Ketogenic Diet | High-fat, very low-carbohydrate diet that alters brain metabolism and excitability | Can significantly reduce seizures in many children with drug-resistant epilepsy | Available through supervised clinical programs and dietitian services | Nutritional deficiencies, elevated lipids, constipation, adherence challenges |
Conclusion
The exclusive global licensing of CannEpil for drug-resistant epilepsy represents a pivotal advance in seizure care. It moves a pharmaceutical-grade cannabinoid into coordinated global development, regulatory planning, and commercialization. As a result, patients with refractory seizures gain clearer paths to new treatment options.
Because about thirty percent of people with epilepsy do not respond to standard medicines, innovation is urgent. Therefore, the license’s rights for reformulations, sublicensing, and twenty-year commercialization empower faster clinical trials and real-world studies. Moreover, investment commitments and EU-GMP manufacturing support stronger supply chains and reimbursement discussions. Consequently, physicians may gain validated cannabinoid options to tailor therapy for refractory cases.
However, rigorous trials and regulatory review remain essential to confirm long-term safety and benefits. But progress now looks hopeful because coordinated global development speeds evidence generation. In short, CannEpil exclusive global licensing for drug-resistant epilepsy could expand access, catalyze innovation, and restore hope for many patients. Patients, advocates, and clinicians now have a clearer roadmap toward new options. Learn more at myCBDadvisor.
Frequently Asked Questions (FAQs)
What is CannEpil exclusive global licensing for drug-resistant epilepsy?
CannEpil exclusive global licensing for drug-resistant epilepsy gives Splash Beverage Group sole worldwide rights to develop and commercialize CannEpil. Therefore, Splash can pursue clinical trials, regulatory filings, reformulations, and sublicensing globally. This arrangement aims to speed availability for patients with refractory seizures.
Is CannEpil safe for patients with drug-resistant epilepsy?
Early evidence shows CannEpil has a tolerable safety profile in observational and early clinical use. However, long-term safety needs confirmation through randomized trials. For context on safety evaluation standards for epilepsy therapies, see the World Health Organization fact sheet.
Where is CannEpil currently available and how can patients access it?
CannEpil is available in Ireland, the United Kingdom, Germany, and Australia under regulated frameworks. In Ireland, eligible patients may access it via the Medicinal Cannabis Access Programme; see HSE guidance.
What does drug-resistant epilepsy mean and who is affected?
Drug-resistant epilepsy describes seizures that persist after two appropriate antiseizure medicines. Consequently, nearly one in three people with epilepsy may meet this definition, and they often need alternative therapies. The Epilepsy Foundation explains this definition and care pathways.
Will CannEpil be covered by insurance and how much will it cost?
Coverage depends on each country and payer policies, and reimbursement varies. Because the license supports global commercialization and local reimbursement engagement, payor discussions will follow approval. Therefore, patients should consult their clinician and national reimbursement programs for specific cost details.
